25 - 28 June 2014 Barcelona
![]() |
![]() |
![]() |
![]() |
1-PD | Cetuximab every 2 weeks with first-line chemotherapy in APEC study patients with metastatic colorectal cancer grouped according to EGFR expression | Lucy Kilpatrick | ![]() |
![]() |
|||
2-PD | KRAS/NRAS and BRAF mutations in the 20050181 study of panitumumab FOLFIRI for the 2nd-line treatment of metastatic colorectal cancer: Updated analysis | Marc Peeters | ![]() |
![]() |
|||
2-P | Detection of c-KIT and PDGFRa mutations in GIST by Next Generation Sequencing. | celine de rop | ![]() |
![]() |
|||
3-PD | Real-life use of cetuximab in 1st-line treatment of unresectable metastatic colorectal cancer (mCRC) and outcomes after surgical resection of metastases: Updated data from the EREBUS cohort | Denis Smith | ![]() |
![]() |
|||
4-PD | The PRIME study: Survival outcomes in patients with KRAS/NRAS wild-type metastatic colorectal cancer and non-liver-limited disease | Jean-Yves Douillard | ![]() |
![]() |
|||
5-PD | Phase II study of single agent cetuximab in KRAS G13D mutant metastatic colorectal cancer (mCRC) | Marta Schirripa | ![]() |
![]() |
|||
6-P | MicroRNA Expression Analysis in Gastric Cancer Using Clustering Method Based on Microarray Data | Sally Yepes | ![]() |
![]() |
|||
6-PD | Panitumumab plus FOLFOX4 or panitumumab plus FOLFIRI in subjects with wild-type KRAS (exon 2) colorectal cancer and multiple or unresectable liver-limited metastases: data from the randomized, phase II PLANET study | Montse Armengol | ![]() |
![]() |
|||
7-O | Subgroup analyses in RAS mutant, BRAF mutant and all wt metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study | Chiara Cremolini | ![]() |
![]() |
|||
9-O | Phase I study of the investigational anti-guanylyl cyclase C (GCC) antibody-drug conjugate (ADC) MLN0264 in adult patients with advanced gastrointestinal malignancies expressing GCC | Jason Faris | ![]() |
![]() |
|||
9-P | Real-world treatment patterns among patients with advanced gastric cancer in Taiwan | Christine Collins | ![]() |
![]() |
|||
10-O | AXE Beam: Neo-adjuvant triplet versus doublet therapy with radiation and total mesorectal excision for locally advanced rectal cancer a randomized phase II study at the end of recruitment | Gabriela Chiritescu | ![]() |
![]() |
|||
11-PD | Circulating tumor cells (CTCs) as prognostic biomarker in patients with advanced chemorefractory, RAS wild-type colorectal cancer (CRC) treated with cetuximab or panitumumab | Valeria Musella | ![]() |
![]() |
|||
12-O | Are the Benefits of Aspirin in Colorectal Cancer limited to PIK3CA Mutated Tumours? | Ruth Langley | ![]() |
![]() |
|||
13-PD | Endoscopic treatment of early esophageal carcinoma: a prospective evaluation of 47 consecutive cases with promising results in patients with T1b cancers | Jana Krajciova | ![]() |
![]() |
|||
13-O | Dietary fatty acids intake and colorectal cancer risk: the Rotterdam Study | Bledar Kraja | ![]() |
![]() |
|||
14-PD | Clinical advantages of laparoscopic colorectal cancer surgery for the high elderly patients over 85 years old | Mr Tomizawa | ![]() |
![]() |
|||
16-PD | TUMOR BUDDING IN COLORECTAL CANCER WITH REGARDS TO MISMATCH REPAIR STATUS PROGNOSTIC VALUE? | Mia Karlberg | ![]() |
![]() |
|||
17-P | LOCAL RECURRENCE RATE FOLLOWING TOTAL GASTRECTOMY BY TRANSABDOMINAL APPROACH FOR SIEWERTS TYPE II ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA | Ramiz Bayramov | ![]() |
![]() |
|||
18-P | Evaluation of patient characteristics and 5-years survival rate in patients operated for gastric cancer in Bulgaria | Kostadin Angelov | ![]() |
![]() |
|||
18-PD | An Indirect Treatment Comparison and Cost-effectiveness Analysis Comparing FOLFIRINOX with nab-Paclitaxel plus Gemcitabine for First-line Treatment for Patients with Metastatic Pancreatic Cancer | Sarah Hollmann | ![]() |
![]() |
|||
19-P | Primary gastric lymphomas: About 216 cases. | Ines Ben Safta | ![]() |
![]() |
|||
19-PD | ORGAN PRESERVATION USING CONTACT RADIOTHERAPY FOR EARLY RECTAL CANCER: OUTCOMES OF PATIENTS TREATED AT A SINGLE CENTRE IN THE UNITED KINGDOM | Amandeep Dhadda | ![]() |
![]() |
|||
21-PD | Value of KRAS, BRAF and PIK3CA Mutations and Benefits from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis | Yusuke Sasaki | ![]() |
![]() |
|||
22-P | Pharmacokinetics of sunitinib in patients with liver cirrhosis and hepatocellular carcinoma | Michele Basso | ![]() |
![]() |
|||
23-PD | Validation Study of a Blood-based Gene Expression Signature for Colorectal Cancer Detection | Qinghua XU | ![]() |
![]() |
|||
24-P | Upregulation of C4.4A in hepatocellular carcinoma | Magdalena Grtz | ![]() |
![]() |
|||
27-P | The genetic background of pancreatic cancer: Genes that might be biomarkers or indicators of metastasis to the lung | Panagiotis Apostolou | ![]() |
![]() |
|||
28-P | Subgroup analyses based on liver metastases and the number of metastatic sites from the MPACT phase III trial of nab-paclitaxel plus gemcitabine vs gemcitabine alone for metastatic pancreatic cancer | Michele Patton | ![]() |
![]() |
|||
29-P | nab-Paclitaxel plus gemcitabine vs gemcitabine alone for patients with metastatic pancreatic cancer: influence of primary pancreatic tumor location on efficacy and treatment exposure in the MPACT phase III trial | Michele Patton | ![]() |
![]() |
|||
32-P | Apoptosis and anergy of T cell induced by pancreatic stellate cells derived Galectin-1 in pancreatic cancer | Dong Tang | ![]() |
![]() |
|||
34-P | Folate intake and selected gastrointestinal cancers morbidity in Poland in the years 1960-2010 | Miroslaw Jarosz | ![]() |
![]() |
|||
36-P | Angiogenic markers of response to neoadjuvant therapy and long-term prognosis in locally advance rectal cancers - a critical analysis of available data | Olivia Lock | ![]() |
![]() |
|||
37-P | Malignant lymphoma diagnosed from gastrointestinal biopsy | Kazuhiko Natori | ![]() |
![]() |
|||
40-P | A Phase I dose-escalation and pharmacokinetic Study of S-1 plus nab-Paclitaxel in Patients with Unresectable or Recurrent Gastric Cancer | Kenji Ishido | ![]() |
![]() |
|||
42-P | Efficacy and safety of triweekly docetaxel, oxaliplatin, fluorouracil, and Folinic acid (DOFF) in patients with advanced gastric or gastroesophageal adenocarcinoma.(Poster presentation). | ABLAVI ADANI-IFE | ![]() |
![]() |
|||
44-P | Evaluation of docetaxel, cisplatin and capecitabine (DCX) as perioperative chemotherapy for resectable gastric and esophago-gastric cancer. | Marcelo Garrido | ![]() |
![]() |
|||
45-P | Phase II feasibility study of adjuvant S-1 plus docetaxel repeated for 6 months as adjuvant chemotherapy for Stage III gastric cancer after curative D2 gastrectomy (OGSG 1002) | Yutaka Kimura | ![]() |
![]() |
|||
46-P | Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for Stage III gastric cancer after curative D2 gastrectomy | Shigeyuki Tamura | ![]() |
![]() |
|||
47-P | Perioperative chemotherapy with folfox in resectable gastro-oesophageal adenocarcinoma: an AGEO multicentric retrospective study | Florence MARY | ![]() |
![]() |
|||
49-P | Immediate and long-term outcome of ESD for differentiated intramucosal gastric cancer compared to surgical resection | Sung Min Park | ![]() |
![]() |
|||
52-P | Gastric Cancer in Young Adults: Experience from Nepal | Bishnu Prasad Kandel | ![]() |
![]() |
|||
55-P | Perioperative chemotherapy of resectable gastroesophageal cancer in elderly patients: a retrospective analysis | Catarina Cardoso | ![]() |
![]() |
|||
56-P | Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced gastroesophageal cancer: A retrospective pooled analysis of individual patient data | Silvia Spoerl | ![]() |
![]() |
|||
57-P | Chemotherapy and target therapy of advanced stomach cancer. | Olga Kuznetsova | ![]() |
![]() |
|||
58-P | Single centre experience of palliative chemotherapy for upper gastrointestinal cancer | Victoria Plested | ![]() |
![]() |
|||
59-P | A single centre review of incidence of venous thromboembolism (VTE) in patients receiving palliative chemotherapy for upper gastrointestinal cancers and the impact on outcomes | Victoria Plested | ![]() |
![]() |
|||
60-P | Comparative study between using antracycline based and taxane based regimens as first line therapy for advanced and metastatic gastric cancer. | Abeer Ibrahim | ![]() |
![]() |
|||
66-P | Does biology and location predict chemotherapy benefit? Patients with distal gastric cancer have superior outcome with addition of taxanes into combination chemotherapy while proximal and diffuse gastric cancers dont. | ali murat sedef | ![]() |
![]() |
|||
67-P | Treatment Patterns and Outcomes of Patients with Gastric Cancer in the US: A retrospective analysis of electronic medical record (EMR) data | Lisa Hess | ![]() |
![]() |
|||
69-P | Costs and patterns of gastric cancer care in the US: A retrospective analysis of administrative claims data | Lisa Hess | ![]() |
![]() |
|||
71-P | Gastric cancer risk screening with combined assay for serum anti-Helicobacter pylori IgG antibody and pepsinogen level, so-called ABC method ; Can we need imaging study for gastric cancer screening ? | Takayuki Nakamura | ![]() |
![]() |
|||
73-P | COMPARISON OF THE AVERAGE BODY WEIGHT AND WAIST CIRCUMFERENCE IN PATIENT WITH BARRETTS OESOPHAGUS AND PATIENT WITHOUT LESIONS | Miros&322;aw Jarosz | ![]() |
![]() |
|||
79-P | The risk factors of postoperative external drainage after gastrectomy without prophylactic intra-peritoneal drainage for gastric cancer | Janghee Lee | ![]() |
![]() |
|||
80-P | Treatment outcome after D2 dissection in operable gastric cancer a retrospective analysis. | Shaikat Gupta | ![]() |
![]() |
|||
82-P | Results After D-2 Resection With Spleen And Distal Pancreas Preserved For Gastric Cancer Treatment | Antonio Chiappa | ![]() |
![]() |
|||
83-P | Devine gastric exclusion: for a better palliation in pyloric obstruction | Sara Carvalhal | ![]() |
![]() |
|||
84-P | Impact On Survival Of The Number Of Lymph Nodes Removed In Extended D-2 Lymphadenectomy For Gastric Cancer | Antonio Chiappa | ![]() |
![]() |
|||
85-P | Multicenter phase II study of combination therapy with oral S-1 plus cisplatin in elderly patients with advanced gastric cancer | Satoru Iwasa | ![]() |
![]() |
|||
89-P | Transient elastography (FibroScan) predictor of hepatocellular carcinoma prognosis in patients referred to surgical treatment | Andra Iulia Suceveanu | ![]() |
![]() |
|||
91-P | Incidental Hepatocellular Carcinoma: A hidden foe for liver transplant recipients? | Renata Senkerikova | ![]() |
![]() |
|||
92-P | SURVIVAL OF PATIENTS WITH HEPATOCELLULAR CARCINOMA IN NORTHERN GREECE. THE ROLE OF HBV INFECTION AND THE VALUE OF SORAFENIB IN INTERMEDIATE STAGE OF DISEASE. | Georgios Nalmpantidis | ![]() |
![]() |
|||
93-P | Treatment Outcomes of Patients with Extremely Advanced Inoperable Hepatocellular Carcinoma (HCC) after Yttrium-90 Radioembolization | Victor Lee | ![]() |
![]() |
|||
95-P | Efficacy of continued sorafenib treatment after radiological confirmation of disease progression in patients with advanced hepatocellular carcinoma | Yoshiyuki Wada | ![]() |
![]() |
|||
98-P | Health Related Quality of Life and Survival in Patients Diagnosed with Hepatocellular Carcinoma and Treated with Transarterial Chemoembolization or Yttrium-90 | Kathryn Bress | ![]() |
![]() |
|||
100-P | A retrospective study of liver stereotactic ablative radiotherapy: 21 months of follow-up | Samuel Palumbo | ![]() |
![]() |
|||
101-P | The role of Choi criteria in assessing response to tyrosine kinase inhibitors (TKIs) in patients with advanced hepatocellular carcinoma (HCC) | Fiona McCarthy | ![]() |
![]() |
|||
103-P | Comparison of Hepatic Resection and Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Meta-Analysis of 16,103 Patients | Qinghua Xu | ![]() |
![]() |
|||
105-P | Oral c-Met inhibitor MSC2156119J as monotherapy versus sorafenib in first-line treatment of Asian patients with MET-positive advanced hepatocellular carcinoma and Child-Pugh class A liver function: Phase Ib/II, multicenter, randomized trial | Ann-Lii Cheng | ![]() |
![]() |
|||
106-P | The impact of FOLFIRINOX chemotherapy on the treatment pattern of patients with pancreas cancer seen at a tertiary referral centre in the UK. | Neha Chopra | ![]() |
![]() |
|||
109-P | Performance status remained the most important prognostic factor in pancreas cancer patients, single center experience | &304;brahim Trker | ![]() |
![]() |
|||
112-P | Evaluation of bowel doses in patients undergoing dose escalated post operative Intensity Modulated Radiotherapy in Perimapullary Cancers | AMIT BAHL | ![]() |
![]() |
|||
116-P | Standard clinical practice of FOLFIRINOX in Advanced/Metastatic Pancreatic Cancer (PC) Patients: A Canadian Registry | jean maroun | ![]() |
![]() |
|||
117-P | Gemcitabine(G)-Erlotinib(E) versus Gemcitabine-Erlotinib-Capecitabine(C) in the first line treatment of patients with metastatic pancreatic cancer (mPC): Efficacy and safety results of a phase IIb randomized study from Spanish TTD Collaborative Group | Susana Rodríguez | ![]() |
![]() |
|||
118-P | FOLFIRINOX IN PANCREATIC CANCER: THE NATIONAL CANCER INSTITUTE OF MILAN SINGLE EXPERIENCE. | KATIA FIORELLA DOTTI | ![]() |
![]() |
|||
124-P | LYMPH NODE INVOLVEMENT IN STANDARD LYMPHADENECTOMY FOR RESECTABLE PANCREATIC HEAD ADENOCARCINOMA | Daniel Kostov | ![]() |
![]() |
|||
125-P | A retrospective study of the prognostic value of various pathological and immunohistochemical features in tissue samples from patients with pancreatic neuroendocrine neoplasms | Nizar BAWAHAB | ![]() |
![]() |
|||
127-P | Multimodality treatment approach for locally advanced pancreatic cancer | Alexander Siebenhuener | ![]() |
![]() |
|||
128-P | Prognostic significance of CEA, CA19-9 and CA72-4 serum level before and after preoperative chemotherapy of esophagogastric junction adenocarcinoma | Milada Zemanova | ![]() |
![]() |
|||
130-P | Serum albumin (SA) as a predictor of response to chemotherapy in patients with locally advanced (LA) esophageal cancer. | Erika Ruiz-Garcia | ![]() |
![]() |
|||
132-P | Is a complete remission of intestinal metaplasia a suitable endpoint in patients undergoing radiofrequency ablation (RFA)? Long-term results of RFA treatment in 67 consecutive patients | Jana Krajciova | ![]() |
![]() |
|||
135-P | Phase I trial of 5-FU, Docetaxel and Nedaplatin combination therapy for metastatic esophageal cancer | Shinichi Nishina | ![]() |
![]() |
|||
137-P | LOCAL ADVANCED ESOPHAGEAL CANCER: PRECISE PREDICTION OF 5-YEAR SURVIVAL AFTER COMBINED ESOPHAGOGASTRECTOMIES | Oleg Kshivets | ![]() |
![]() |
|||
141-P | Electroneurography in evaluation of peripheral neuropathy during oxaliplatin-based chemotherapy for colorectal cancer. | Aneta Zygulska | ![]() |
![]() |
|||
146-P | To select the therapies in gastric carcinoid tumors | Sei Kurokawa | ![]() |
![]() |
|||
148-P | Presentation of Insulinoma in developing world | Manish Kaushal | ![]() |
![]() |
|||
149-P | Anorectal malignant melanoma experience of a single portuguese institution | Isália Miguel | ![]() |
![]() |
|||
151-P | Gastric neuroendocrine tumors: a single center experience. | IOANNIS PILPILIDIS | ![]() |
![]() |
|||
158-P | Image-guided hypofractionated stereotactic ablative radiotherapy for the liver: the MAASTRO experience | Lien Van De Voorde | ![]() |
![]() |
|||
159-P | Diagnosis, staging and treatment of cholangiocarnioma; a retrospective analysis of our last decade of experience | Heppell Hebert Mathieu | ![]() |
![]() |
|||
160-P | GASTROINTESTINAL CANCERS: EPIDEMIOLOGICAL, CLINICAL, HISTOLOGICAL AND THERAPEUTIC CHARACTERISTIC (210 CASES TREATED IN THE RADIOTHERAPY DEPARTMENT OF UNIVERSITY HOSPITAL OF HASSAN II-FES-MOROCCO BETWEEN JANUARY 2012 AND DECEMBER 2013) | fatima zahra farhane | ![]() |
![]() |
|||
161-P | The provision of a pre-operative immunomodulating diet in patients undergoing radical resection for upper gastrointestinal cancers does not reduce the risk of post-operative chest infection | Petra Goldsmith | ![]() |
![]() |
|||
167-P | INTERNATIONAL SCIENTIFIC COMMUNICATIONS IN THE FIELD OF RECTAL CANCER PATIENTS QUALITY OF LIFE | Daniel Kostov | ![]() |
![]() |
|||
168-P | INTERNATIONAL VISIBILITY OF RESEARCH ON INTERSPHINCTERIC RESECTIONS FOR RECTAL CANCER | Daniel Kostov | ![]() |
![]() |
|||
169-P | Neoadjuvant chemoradiation for rectal cancers | Charu Singh | ![]() |
![]() |
|||
170-P | EPIDEMIOLOGY OF RECTAL CANCER IN THE REGIONS OF VARNA AND DOBRICH, BULGARIA | Daniel Kostov | ![]() |
![]() |
|||
171-P | Incidence of Kirsten-Ras Gene Mutation and Its Association with Clinical and Pathological Factors in Colorectal Carcinoma: single institute retrospective experience | Vinayak Maka | ![]() |
![]() |
|||
174-P | Association between colorectal cancer survival outcomes and GWAS-identified colorectal cancer susceptibility polymorphism in Korean population | Byung Woog Kang | ![]() |
![]() |
|||
175-P | Simultaneous detection of KRAS, NRAS and BRAF hotspot mutations on Ion Torrent PGM platform. | celine de rop | ![]() |
![]() |
|||
176-P | The levels of methionine determined by amino acid profiling correlate with the degree of methylation in colon cancer tissues. | Yuji Takayama | ![]() |
![]() |
|||
177-P | KRAS Mutation Status in Colombian patients with colorectal cancer: Analysis of 844 consecutive cases | Rocío del Pilar López Panqueva | ![]() |
![]() |
|||
179-P | Intronic SMAD7 gene polymorphisms, rs12953717 and rs4464148, in association with risk of Colorectal Cancer | Shaghayegh Derakhshani | ![]() |
![]() |
|||
180-P | BEVACIZUMAB IN COMBINATION WITH IRINOTECAN AND CAPECITABINE AS FIRST-LINE TREATMENT FOR mCRC EFFICACY AND SAFETY | SAA JUNGI&262; | ![]() |
![]() |
|||
181-P | Detention of molecular changes between primary tumor (PT) and synchronous resected liver metastases (srLm) in colo-rectal cancer (CRC) patients after first line cetuximab based chemotherapy (CT). | DANIELA ADUA | ![]() |
![]() |
|||
184-P | Selective, synergic and additive interaction types between 5-fluorouracil and 2-oxohexyl isothiocyanate after sequential treatment in colon cancer cell lines | Ma&322;gorzata Milczarek | ![]() |
![]() |
|||
185-P | Combined administration of 5-fluorouracil as well as 2-oxohexyl isothiocyanate with selol give synergistic toxic effect on HT -29 colorectal cancer cell lines. | Lidia Sliwka | ![]() |
![]() |
|||
187-P | Incidence of Hepatic Resection among Colorectal Cancer Patients with Liver Metastases | Keith Betts | ![]() |
![]() |
|||
188-P | Isothiocyanates are chemopreventive compounds and reduce the MDR phenomenon - study on normal and colon cancer cells | Katarzyna Lubelska | ![]() |
![]() |
|||
191-P | Is there a trend toward lower participation in colorectal cancer screening among certain populations? | Olivier Galut | ![]() |
![]() |
|||
192-P | ABDOMINAL OBESITY IS ASSOCIATED WITH THE NUMBER OF COLORECTAL POLYPS IN MEN BUT NOT IN WOMEN | Miros&322;aw Jarosz | ![]() |
![]() |
|||
194-P | KRAS genotype and the prevalent c.35 G A mutation affect significantly worse prognosis of metastatic colorectal cancer (MCRC) patients fitting for intensive FIr-B/FOx triplet chemotherapy plus bevacizumab. | Gemma Bruera | ![]() |
![]() |
|||
195-P | Clinical validation of a novel multiplex kit for all RAS mutations in colorectal cancer: Results of RASKET (RAS KEy Testing) prospective multicenter study | Toshihiro Kudo | ![]() |
![]() |
|||
196-P | Expression of aquaporin-1, aquaporin-3, and aquaporin-5 with nodal metastasis in colon cancer | Byung Woog Kang | ![]() |
![]() |
|||
197-P | Comparison of a new multiplexed multigene approach with pyrosequencing in diagnostic molecular biology of colorectal cancer (CRC) | Giovanna De Maglio | ![]() |
![]() |
|||
198-P | KRAS mutations in colorectal cancer patients in Serbia: 5 years experience of central testing | Radmila Jankovic | ![]() |
![]() |
|||
199-P | Analysis of Molecular Alterations for Predicting Clinical Benefit to Cetuximab plus Chemotherapy in first-line Metastatic Colorectal Cancer (mCRC) | Javier Sastre | ![]() |
![]() |
|||
202-P | Cyclooxygenase-2 (COX-2) expression in a cohort of Greek patients with colorectal cancer (CRC) | DIMITRIOS TZILVES | ![]() |
![]() |
|||
203-P | Value of monitoring CEA in patients with colon cancer receiving adjuvant chemotherapy | Andrea Nagy | ![]() |
![]() |
|||
205-P | Cytokines, depression and anxiety in colorectal cancer patients in different stages of the antitumor therapy | Dr. Miranda | ![]() |
![]() |
|||
206-P | Hyperuricemia at time of diagnosis is a poor prognostic factor for patients with colorectal cancer: a pilot study | Ozgur Tanriverdi | ![]() |
![]() |
|||
209-P | Tolerability and Safety of cytotoxic chemotherapy in patients over 80 with colorectal cancer (CRC) at Heart of England NHS Foundation Trust (HEFT) | Racha Kussaibati | ![]() |
![]() |
|||
210-P | Under prescription of targeted therapy in first-line metastatic colorectal cancer in elderly people: a cohort study in a French center. | Amaury daste | ![]() |
![]() |
|||
211-P | Prespecified subgroup analyses in WJOG4407G trial, a randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab in first-line treatment for metastatic colorectal cancer | HIROSHI TAMAGAWA | ![]() |
![]() |
|||
213-P | COLORECTAL CANCER IN PATIENTS AGE 40 AND UNDER: A RETROSPECTIVE ANALYSIS OF DATABASE FROM THE INSTITUTE OF ONCOLOGY AND RADIOLOGY OF SERBIA | Jelena Spasic | ![]() |
![]() |
|||
214-P | Use of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer (mCRC): a post-hoc analysis of the GLUTOX study | Francois Leblond | ![]() |
![]() |
|||
215-P | Efficacy, safety and patient-reported outcomes of oxaliplatin-based chemotherapy in elderly patients with colorectal cancer (CRC): a post-hoc analysis of the GLUTOX study | Francois Leblond | ![]() |
![]() |
|||
216-P | Evaluating the learning curve of Magnetic Resonance Imaging (MRI) as a predictive tool in locally advanced rectal cancer (RC) - a retrospective 12-year experience. | CHA LEN LEE | ![]() |
![]() |
|||
220-P | The sequential administration of XELOX and XELIRI was effective, feasible and manageable for patients with mCRC. | Taro Fukui | ![]() |
![]() |
|||
223-P | Survival advantage of metformin in patients with colorectal cancer and type II diabetes mellitus: The Middle Eastern perspective. | Ali Shamseddine | ![]() |
![]() |
|||
230-P | Salvage chemotherapy in metastatic colorectal cancer with combination of capecitabine and mitomycin C. | Aneta Zygulska | ![]() |
![]() |
|||
231-P | Efficacy and safety of bevacizumabhepatic arterial infusion chemotherapy of FOLFIRI for unresectable colorectal liver metastases | Yoshiyuki Wada | ![]() |
![]() |
|||
232-P | Extending targeted therapy beyond first-line (1L) chemotherapy backbone: real-world treatment patterns and outcomes in patients with metastatic colorectal cancer (mCRC) | Manasee Shah | ![]() |
![]() |
|||
233-P | Assessment of morphological response contributes to selection of candidates for rescue liver resection among patients undergoing chemotherapy for initially unresectable colorectal liver metastasis | Koichi Suzuki | ![]() |
![]() |
|||
234-P | Analysis of Glasgow Prognostic Score(GPS) in KRAS Exon2 wild type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901 | SATOSHI YUKI | ![]() |
![]() |
|||
236-P | The PRIME study: Survival outcomes for patients with RAS/BRAF wild-type metastatic colorectal cancer, by baseline ECOG performance status | Marc Peeters | ![]() |
![]() |
|||
237-P | Cost effectiveness of Selective Internal Radiation Therapy (SIRT) using yttrium-90 resin microspheres for the treatment of patients with inoperable colorectal liver metastases in the UK | Karin Sennfalt | ![]() |
![]() |
|||
238-P | Cost effectiveness of Selective Internal Radiation Therapy (SIRT) using yttrium-90 resin microspheres for the treatment of patients with inoperable colorectal liver metastases in Italy | Karin Sennfalt | ![]() |
![]() |
|||
244-P | Single institution results of first- line treatment with bevacizumab plus chemotherapy in metastatic colorectal cancer (mCRC) | Jaroslava Barkmanova | ![]() |
![]() |
|||
246-P | Management of patients with colorectal liver metastasis harboring more than 5 multiple tumors | Kosuke Ichida | ![]() |
![]() |
|||
248-P | Cetuximab with irinotecan or oxaliplatin for 1st-line metastatic colorectal cancer: updated data of effectiveness in the EREBUS cohort compared to pivotal trials | Denis Smith | ![]() |
![]() |
|||
249-P | Conversion chemotherapy for technically unresectable colorectal liver metastases: a retrospective, single-center study comparing chemotherapy alone or in combination with cetuximab or bevacizumab. | Vincenzo Dadduzio | ![]() |
![]() |
|||
250-P | Bevacizumab in combination with neoadjuvant therapy in elderly patients with liver metastases of colorectal cancer-Single center experience | marija ristic | ![]() |
![]() |
|||
251-P | Bevacizumab in the first line therapy of metastatic colorectal cancer in older patients, study AVEX in clinical practice. | Lenka Ost&345;íková | ![]() |
![]() |
|||
252-P | Cost-effectiveness of different chemotherapy strategies for patients with advanced colorectal cancer in Brazil: a Public Health System perspective | Andre Sasse | ![]() |
![]() |
|||
259-P | Safety analysis of FOLFOX as adjuvant chemotherapy for stage III colon cancer in North Japan multicenter phase II study (NORTH/HGCSG1003) | Norihiko Takahashi | ![]() |
![]() |
|||
261-P | The management of peritoneal surface malignancies at the American University of Beirut Medical Center: initial experience | Faek Jamali | ![]() |
![]() |
|||
266-P | Adjuvant regorafenib in stage IV colorectal cancer (CRC) after curative treatment of liver metastases: A phase III randomized, placebo-controlled study (COAST) | Eric Van Cutsem | ![]() |
![]() |
|||
267-P | Dose-dense temozolomide (TMZ) in patients with advanced chemorefractory colorectal cancer (CRC) and MGMT promoter methylation | Filippo Pietrantonio | ![]() |
![]() |
|||
269-P | The CAIRO4 study: The role of surgery of the primary tumor with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer: a randomized phase III study. | Jorine t Lam - Boer | ![]() |
![]() |
|||
272-P | Neoadjuvant Chemotherapy capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer | Takeshi Kato | ![]() |
![]() |
|||
275-P | Clinical significance of tumour regression grade in locally-advanced rectal cancer treated with preoperative chemoradiotherapy | ALBA HERNANDEZ | ![]() |
![]() |
|||
279-P | Ordinary rectal adenocarcinoma vs. primary rectal signet-ring cell carcinoma | LOUKILI KAOUTAR | ![]() |
![]() |
|||
10008-O | Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone, as second-line treatment for patients with KRAS wild-type metastatic colorectal cancer: the POSEIDON Phase I/randomized Phase II trial | Elena Elez | ![]() |
![]() |
|||
10243-P | Deep responders represent a group with excellent survival in patients with metastatic colorectal cancer(mCRC) treated with Triplet chemotherapy regimens(TCR) | Shouki Bazarbashi | ![]() |
![]() |
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |